vs
Revvity（RVTY）与Rackspace Technology, Inc.（RXT）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是Rackspace Technology, Inc.的1.1倍（$772.1M vs $682.8M），Revvity净利率更高（12.7% vs -4.8%，领先17.5%），Revvity同比增速更快（5.9% vs -0.4%），Revvity自由现金流更多（$161.8M vs $56.0M），过去两年Revvity的营收复合增速更高（9.0% vs -0.6%）
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
Rackspace Technology, Inc.是总部位于美国得克萨斯州圣安东尼奥的云计算企业，在弗吉尼亚州雷斯顿以及澳大利亚、加拿大、英国、印度、迪拜、瑞士、荷兰、德国、新加坡、墨西哥、中国香港等多个国家和地区设有办事处，数据中心分布于全球多个主要城市，为客户提供专业的云计算相关服务。
RVTY vs RXT — 直观对比
营收规模更大
RVTY
是对方的1.1倍
$682.8M
营收增速更快
RVTY
高出6.3%
-0.4%
净利率更高
RVTY
高出17.5%
-4.8%
自由现金流更多
RVTY
多$105.8M
$56.0M
两年增速更快
RVTY
近两年复合增速
-0.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $772.1M | $682.8M |
| 净利润 | $98.4M | $-32.7M |
| 毛利率 | — | 17.6% |
| 营业利润率 | 14.5% | -0.5% |
| 净利率 | 12.7% | -4.8% |
| 营收同比 | 5.9% | -0.4% |
| 净利润同比 | 3.9% | 41.6% |
| 每股收益（稀释后） | $0.86 | $-0.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收RVTYRXT
| Q4 25 | $772.1M | $682.8M | ||
| Q3 25 | $698.9M | $671.2M | ||
| Q2 25 | $720.3M | $666.3M | ||
| Q1 25 | $664.8M | $665.4M | ||
| Q4 24 | $729.4M | $685.6M | ||
| Q3 24 | $684.0M | $675.8M | ||
| Q2 24 | $691.7M | $684.9M | ||
| Q1 24 | $649.9M | $690.8M |
净利润RVTYRXT
| Q4 25 | $98.4M | $-32.7M | ||
| Q3 25 | $46.7M | $-67.1M | ||
| Q2 25 | $53.9M | $-54.5M | ||
| Q1 25 | $42.2M | $-71.5M | ||
| Q4 24 | $94.6M | $-56.0M | ||
| Q3 24 | $94.4M | $-186.6M | ||
| Q2 24 | $55.4M | $25.0M | ||
| Q1 24 | $26.0M | $-640.6M |
毛利率RVTYRXT
| Q4 25 | — | 17.6% | ||
| Q3 25 | 53.6% | 19.4% | ||
| Q2 25 | 54.5% | 19.4% | ||
| Q1 25 | 56.5% | 19.1% | ||
| Q4 24 | — | 19.2% | ||
| Q3 24 | 56.3% | 20.3% | ||
| Q2 24 | 55.7% | 19.2% | ||
| Q1 24 | 54.6% | 19.2% |
营业利润率RVTYRXT
| Q4 25 | 14.5% | -0.5% | ||
| Q3 25 | 11.7% | -5.1% | ||
| Q2 25 | 12.6% | -3.8% | ||
| Q1 25 | 10.9% | -5.8% | ||
| Q4 24 | 16.3% | -4.2% | ||
| Q3 24 | 14.3% | -25.7% | ||
| Q2 24 | 12.4% | -7.9% | ||
| Q1 24 | 6.8% | -94.5% |
净利率RVTYRXT
| Q4 25 | 12.7% | -4.8% | ||
| Q3 25 | 6.7% | -10.0% | ||
| Q2 25 | 7.5% | -8.2% | ||
| Q1 25 | 6.4% | -10.7% | ||
| Q4 24 | 13.0% | -8.2% | ||
| Q3 24 | 13.8% | -27.6% | ||
| Q2 24 | 8.0% | 3.7% | ||
| Q1 24 | 4.0% | -92.7% |
每股收益（稀释后）RVTYRXT
| Q4 25 | $0.86 | $-0.13 | ||
| Q3 25 | $0.40 | $-0.28 | ||
| Q2 25 | $0.46 | $-0.23 | ||
| Q1 25 | $0.35 | $-0.31 | ||
| Q4 24 | $0.77 | $-0.20 | ||
| Q3 24 | $0.77 | $-0.82 | ||
| Q2 24 | $0.45 | $0.11 | ||
| Q1 24 | $0.21 | $-2.91 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $919.9M | $105.8M |
| 总债务越低越好 | — | $2.7B |
| 股东权益账面价值 | $7.3B | $-1.2B |
| 总资产 | $12.2B | $2.8B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资RVTYRXT
| Q4 25 | $919.9M | $105.8M | ||
| Q3 25 | $931.4M | $99.5M | ||
| Q2 25 | $991.8M | $103.9M | ||
| Q1 25 | $1.1B | $128.0M | ||
| Q4 24 | $1.2B | $144.0M | ||
| Q3 24 | $1.2B | $157.1M | ||
| Q2 24 | $2.0B | $190.2M | ||
| Q1 24 | $1.7B | $282.6M |
总债务RVTYRXT
| Q4 25 | — | $2.7B | ||
| Q3 25 | — | $2.8B | ||
| Q2 25 | — | $2.8B | ||
| Q1 25 | — | $2.8B | ||
| Q4 24 | — | $2.8B | ||
| Q3 24 | — | $2.8B | ||
| Q2 24 | — | $2.9B | ||
| Q1 24 | — | $3.0B |
股东权益RVTYRXT
| Q4 25 | $7.3B | $-1.2B | ||
| Q3 25 | $7.4B | $-1.2B | ||
| Q2 25 | $7.6B | $-1.1B | ||
| Q1 25 | $7.6B | $-1.1B | ||
| Q4 24 | $7.7B | $-1.0B | ||
| Q3 24 | $7.9B | $-949.7M | ||
| Q2 24 | $7.9B | $-756.2M | ||
| Q1 24 | $7.8B | $-787.2M |
总资产RVTYRXT
| Q4 25 | $12.2B | $2.8B | ||
| Q3 25 | $12.1B | $2.8B | ||
| Q2 25 | $12.4B | $2.9B | ||
| Q1 25 | $12.4B | $3.0B | ||
| Q4 24 | $12.4B | $3.1B | ||
| Q3 24 | $12.8B | $3.1B | ||
| Q2 24 | $13.4B | $3.4B | ||
| Q1 24 | $13.4B | $3.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $182.0M | $59.7M |
| 自由现金流经营现金流 - 资本支出 | $161.8M | $56.0M |
| 自由现金流率自由现金流/营收 | 21.0% | 8.2% |
| 资本支出强度资本支出/营收 | 2.6% | 0.5% |
| 现金转化率经营现金流/净利润 | 1.85× | — |
| 过去12个月自由现金流最近4个季度 | $509.4M | $90.6M |
8季度趋势，按日历期对齐
经营现金流RVTYRXT
| Q4 25 | $182.0M | $59.7M | ||
| Q3 25 | $138.5M | $70.7M | ||
| Q2 25 | $134.3M | $8.4M | ||
| Q1 25 | $128.2M | $12.6M | ||
| Q4 24 | $174.2M | $54.3M | ||
| Q3 24 | $147.9M | $51.8M | ||
| Q2 24 | $158.6M | $24.1M | ||
| Q1 24 | $147.6M | $-90.3M |
自由现金流RVTYRXT
| Q4 25 | $161.8M | $56.0M | ||
| Q3 25 | $120.0M | $42.7M | ||
| Q2 25 | $115.5M | $-12.4M | ||
| Q1 25 | $112.2M | $4.3M | ||
| Q4 24 | $149.8M | $34.4M | ||
| Q3 24 | $125.6M | $27.3M | ||
| Q2 24 | $136.6M | $-14.5M | ||
| Q1 24 | $129.7M | $-118.4M |
自由现金流率RVTYRXT
| Q4 25 | 21.0% | 8.2% | ||
| Q3 25 | 17.2% | 6.4% | ||
| Q2 25 | 16.0% | -1.9% | ||
| Q1 25 | 16.9% | 0.6% | ||
| Q4 24 | 20.5% | 5.0% | ||
| Q3 24 | 18.4% | 4.0% | ||
| Q2 24 | 19.7% | -2.1% | ||
| Q1 24 | 20.0% | -17.1% |
资本支出强度RVTYRXT
| Q4 25 | 2.6% | 0.5% | ||
| Q3 25 | 2.6% | 4.2% | ||
| Q2 25 | 2.6% | 3.1% | ||
| Q1 25 | 2.4% | 1.2% | ||
| Q4 24 | 3.4% | 2.9% | ||
| Q3 24 | 3.3% | 3.6% | ||
| Q2 24 | 3.2% | 5.6% | ||
| Q1 24 | 2.7% | 4.1% |
现金转化率RVTYRXT
| Q4 25 | 1.85× | — | ||
| Q3 25 | 2.97× | — | ||
| Q2 25 | 2.49× | — | ||
| Q1 25 | 3.03× | — | ||
| Q4 24 | 1.84× | — | ||
| Q3 24 | 1.57× | — | ||
| Q2 24 | 2.87× | 0.96× | ||
| Q1 24 | 5.67× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
RXT
| Public Cloud Services Segment | $442.2M | 65% |
| Private Cloud Service Segment | $240.6M | 35% |
